Immugenia
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immugenia - overview
Established
2022
Location
-, QC, Canada
Primary Industry
Healthcare Specialists
About
Based in Canada, and founded in 2022 by its CEO Stéphane Gagné and co-founder Brigitte Lemieux, Immugenia Inc. operates as an early-stage immuno-oncology company that develops CAR therapy. In October 2022, Immugenia Inc. raised venture funding from ACET Capital, adMare Bioinnovations and Sherbrooke Innopole.
Immugenia Inc. develops CAR (chimeric antigen receptor) therapy which involves immune cells from a cancer patient and modifying them to express a CAR, making it possible to recognize and kill cancer cells when injected back into the patient. Its technology allows for the CAR to be expressed selectively in T and NK cells in order to leverage their synergistic activity against cancer. In addition, the company has created a biotechnological tool enabling the use of hematopoietic stem cells to treat life-threatening cancers.
The company plans to use venture funding to develop a cancer treatment which would prevent relapses.
Current Investors
adMare Bioinnovations , Sherbrooke Innopole, ACET Capital
Primary Industry
Healthcare Specialists
Sub Industries
Biotechnology, Oncology/Cancer Treatment, Medical Software
Website
www.immugenia.com
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.